" 314.96 
amendments to an unapproved abbreviated application. 
(a) abbreviated new drug application. (1) an applicant may amend an abbreviated new drug application that is submitted under  314.94, but not yet approved, to revise existing information or provide additional information. amendments containing bioequivalence studies must contain reports of all bioequivalence studies conducted by the applicant on the same drug product formulation, unless the information has previously been submitted to fda in the abbreviated new drug application. a complete study report must be submitted for any bioequivalence study upon which the applicant relies for approval. for all other bioequivalence studies conducted on the same drug product formulation as defined in  320.1(g) of this chapter, the applicant must submit either a complete or summary report. if a summary report of a bioequivalence study is submitted and fda determines that there may be bioequivalence issues or concerns with the product, fda may require that the applicant submit a complete report of the bioequivalence study to fda. 
(2) submission of an amendment containing significant data or information before the end of the initial review cycle constitutes an agreement between fda and the applicant to extend the initial review cycle only for the time necessary to review the significant data or information and for no more than 180 days. 
(b) the applicant shall submit a field copy of each amendment to  314.94(a)(9). the applicant, other than a foreign applicant, shall include in its submission of each such amendment to fda a statement certifying that a field copy of the amendment has been sent to the applicant's home fda district office. 

